INTRODUCTION
In advanced breast cancer, chemotherapies, such as methotrexate (MTX), are detrimental to the gut microbiota [1] and bone microarchitecture, increasing fracture risk [2]. Interplay between the gastrointestinal and skeletal systems, termed the “gut-bone axis”, may reciprocally influence chemotherapy [3].
Given 90% of individuals treated for breast cancer with chemotherapy survive five-years post-diagnosis, understanding the effects of chemotherapies on bone is essential [4]. Diets that support gut health during chemotherapy may also be effective at mitigating bone loss. Thus, this study aimed to determine the effect of MTX +/- a hydrolysed protein (HP) diet on trabecular bone in long bones of a rat breast cancer model.
METHODS
Female dark agouti rats (n=32) were subcutaneously inoculated with mammary adenocarcinoma cells [5] then allocated to; vehicle control (VC; n=8), HP diet only (NT; n=8), MTX only (MTX; 2 mg/kg intramuscularly; n=8), and HP diet and MTX combination (NTMTX; n=8).
Rodents were given standard or HP diet (Nutricia Research) starting on day -14 then treated on days 0 and 1 with either MTX or vehicle and euthanised on day 4. Long bones were scanned via micro-CT and assessed for; trabecular thickness (Tb.Th.), trabecular number (Tb.N.), trabecular spacing (Tb.S.), bone volume (BV), and percent bone volume (BV/TV%).
RESULTS
A significant increase in Tb.Th. (p=0.0101), Tb.N. (p=0.0198), and BV/TV% (p=0.0054) was observed in NT rat tibia. No significant differences were observed in MTX and NTMTX rat tibia or femur.
Figure 1: (A) High resolution 3D micro-CT models of right tibia; (i) VC (ii) NT (iii) MTX and (iv) NTMTX. (B) Histomorphometric analysis of right tibia trabecular microarchitecture by high resolution micro-CT. (i) Tb.Th. (ii) Tb.N. (iii) Tb.S. (iv) BV (v) BV/TV%.
CONCLUSION
Results indicate that HP diet increases bone volume, which may have a protective effect against MTX-induced bone loss.